Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × Fulvestrant × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 27 Ovarian Neoplasms 7 Neoplasms 6 Neoplasm Metastasis 6 Endometrial Neoplasms 6 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Prostatic Neoplasms 3 Neoplasms by Site 3 Breast Diseases 3 Triple Negative Breast Neoplasms 2 Hereditary Sensory and Autonomic Neuropathies 2 Head and Neck Neoplasms 2 Uterine Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Melanoma 1 Malignant Neoplasms of Female Genital Organs 1 Lung Neoplasms 1 Locoregional Recurrence 1 HR+/HER2- Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 Genital Neoplasms, Female 1 Fallopian Tube Neoplasms 1 Exanthema 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Esophageal Squamous Cell Carcinoma 1

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡